Bharat Biotech will hold a meeting with the World Health Organization (WHO) today on the recognition of anti-coronavirus vaccine Covaxin. In this meeting, Covaxin will be evaluated for Emergency Use List (EUL). Covaxin has been developed by Bharat Biotech in association with Indian Council of Medical Research. It has been found to be 77.8% effective in the third phase trial. Bharat Biotech had submitted the trial data to the Drug Controller General of India last week. On Tuesday, the Subject Expert Committee (SEC) approved the data of the Phase 3 trial of the vaccine. At present, three vaccines are being used in India’s COVID-19 vaccination programme. These are Covaxin, Covishield and Sputnik-V vaccines.